Horizon Therapeutics Grows Portfolio with Massive Acquisition

It’s exciting to watch our partners at Horizon Therapeutics grow. The company’s new $3.1 billion purchase of a Maryland-based drug maker is a tremendous boost to an already-robust portfolio of rare disease treatments.

Click here to learn more.